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Abstract Yellow discoloration of the skin may be caused
by several etiologies, including jaundice, hypervitaminosis,
drug reaction or chemical exposure. Herein we describe a
68-year-old woman with a history of breast and thyroid
carcinoma, presenting with a yellow discoloration of her
soles, after ingestion of one capsule a day of turmeric root
extract (Bluebonnet Turmeric Root, 500 mg, Vcap), taken
for its anti-cancer properties, for 4 months. After drug
cessation, the yellow hue disappeared completely.
A Naranjo assessment score of 5 was obtained, indicating a
probable relationship between the patient’s symptom and
her use of the drug. Curcumin, a mixture of difer-
uloymethane derivatives known as curcuminoids, is a
yellow pigment present in the spice turmeric. Topical ap-
plication of curcumin to the human skin is joined by or-
ange-yellow discoloration. To the best of our knowledge,
yellow skin discoloration after oral intake of turmeric is not
mentioned in the medical literature.
Key Points
Turmeric root extract contains curcuminoids, a
mixture of diferuloymethane derivatives that gives it
its yellow pigment.
Topical application of curcuminoids to the human
skin is joined by orange-yellow discoloration.
We describe a patient in which a yellow
discoloration of the soles is attributed to the oral
consumption of a 500 mg capsule of turmeric root
extract daily, for 4 months. A Naranjo assessment
score of 5 indicates a probable relationship between
the patient’s symptom and her use of the drug.
Introduction
Skin discoloration is infrequently observed in the setting of
a dermatology clinic. It may be generalized or localized
and may have different hues such as yellow, grey or bluish.
Differential diagnosis may be wide. Herein we describe a
patient with breast and thyroid carcinoma, presenting with
yellow discoloration of her soles due to oral ingestion of
turmeric (curcumin).
Case Report
A 68-year-old woman presented to the dermatology out-
patient clinic with a 3-month history of yellow discol-
oration of her soles. Ten years earlier, a breast carcinoma
was diagnosed, and she was treated surgically and with
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chemotherapy. Three years prior to presentation, a second
primary carcinoma of the thyroid gland was diagnosed and
the patient underwent a second operation.
At the time of presentation, her medicaments included
exemestane (Aromasin), an aromatase inhibitor, an anti-
cancer drug that blocks androgen conversion to estrogen,
and levothyroxine (Eltroxin). She also took a wide variety
of vitamins and dietary supplements, for a prolonged time,
including Ca2?/Mg2? citrate, vitamin D, multi-vitamin, L-
glutamate, omega 3, Ganoderma lucidum (Ling zhi)
mushroom, Polygonatum odoratum (P. officinale) and
white mulberry (Morus alba), the latter three prescribed by
her naturopathic doctor. Turmeric root extract, (Bluebonnet
Turmeric Root, 500 mg, Vcap) was started by her natur-
opath 4 months before presentation, once a day. Bluebon-
net Turmeric Root Extract Vcaps contain 95 %
curcuminoids: curcumin 332 mg, demethoxycurcumin
71 mg, bisdemethoxycurcumin 11 mg, turmeric root
powder (Curcuma C3 Complex, Curcuma longa) 150 mg.
Other ingredients are from the vegetable capsules,
Fruit02X: wild blueberry, cranberry, prune, cherry and
bilberry fruits, grape seed, raspberry seed, vegetable cel-
lulose, calcium phosphate, silica, and vegetable magnesium
stearate. The patient denied administration of any topical
treatment to her feet or any change in her diet.
At physical examination, both feet and toenails showed
a bright yellow discoloration, with hyperkeratotic areas
with a more pronounced pigmentation (Fig. 1). No color
change was present on the palms, conjunctivae or oral
mucosae and tongue. Laboratory work up disclosed the
presence of anemia, with normal liver, kidney and thyroid
function tests, lipids and vitamin A levels. CA-125 (cancer
antigen 125) and CA-15.3 (cancer antigen 15.3) were
mildly elevated.
The patient was advised to stop taking the turmeric root
extract. Two months later the skin discoloration disap-
peared completely.
Discussion
Yellow discoloration of the skin may be caused by several
etiologies, including jaundice, hypervitaminosis, drug re-
action or chemical exposure. In our case, jaundice was
suspected, because the patient has a history of carcinomas,
and could have jaundice due to intra-hepatic or post-hep-
atic metastatic disease. Other possible etiologies include
hemolysis, alcohol ingestion, infectious hepatitis, drug re-
action, autoimmunity, gallstones and biliary tract infection.
However, all different types of jaundice are characterized
by yellow conjunctivae and elevated bilirubin [1].
Although our patient had elevated cancer markers, liver
function tests were normal, and no involvement of the
conjunctivae was evident. The lack of hyperbilirubinemia
excluded completely this diagnosis.
‘Carotenoderma’ is the name given to the yellow dis-
coloration of the skin that is caused by increased serum
carotenoids. Carotenoids are absorbed by passive diffusion
from the gastrointestinal tract and are then partially me-
tabolized in the intestinal mucosa and liver to retinol (vi-
tamin A). From there they are transported in the plasma via
lipoproteins into the peripheral tissues, and in the skin they
are deposited in the intercellular lipids of the stratum
corneum. Therefore, color change is most prominent in
regions of increased sweating and thickness of this layer.
These areas include the palms, soles, knees, and nasolabial
folds. The primary factor differentiating carotenoderma
from jaundice clinically is the characteristic sparing of the
conjunctivae in carotenoderma. Carotenoderma can be di-
vided into primary and secondary carotenoderma. Primary
carotenoderma develops from increased oral ingestion of
foods such as carrots, tomatoes and squash, whereas sec-
ondary carotenoderma is caused by underlying diseases
that increase serum carotenoids with normal oral intake,
such as hypothyroidism, diabetes mellitus, anorexia ner-
vosa, nephrotic syndrome and liver disease. Some of these
diseases have in common an increased level of lipids and
lipoproteins in the serum. Serum vitamin A would be
elevated in all these cases, but was normal in our case,
excluding this diagnosis [2].
Yellow skin discoloration was reported with the use of
several medications, including the multitargeted tyrosine
kinase inhibitors sorafenib and sunitinib [3], trastuzumab
[4], quinacrine and dipyridamole. Canthaxanthin, a car-
otenoid, is authorized in some countries for trout, salmon
Fig. 1 Yellow discoloration of the sole, more pronounced in areas of
hyperkeratotic skin
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and poultry feed and is associated with skin yellowing with
touch. Canthaxanthin has also been used orally as an arti-
ficial tanner because of the orange-tan discoloration it ap-
plies to the skin, but was associated with health problems
and banned. None of the above was taken by our patient.
Among chemical exposures, dinitrophenol or its
derivative, picric acid, methylenedianiline and saffron
(Crocus sativus), are all associated with yellowing of the
skin, hair, and nails at sites of contact [5]. The patient did
not report exposure to any of these agents.
Curcumin, a mixture of diferuloymethane derivatives
known as curcuminoids, is a yellow pigment present in the
spice turmeric (Curcuma longa, C. domestica, Indian saf-
fron), which gives curry powder its color and flavor. It is
added to sunscreens and cosmetics due to its anti-oxidative
properties and is used as food colorant in butter and cheese.
Turmeric has been used in traditional medicine for cen-
turies, thought to harbor anti-oxidant, anti-inflammatory,
anti-cancer, anti-viral, and anti-bacterial qualities. There
are more than 2400 references in PubMed about turmeric
as a cancer suppressor [6]. Curcuminoids are not harmful in
high doses. According to the assessment report on C. longa
of the committee on herbal medicinal products of the
European Medicines Agency, only minor side effects such
as dry mouth, flatulence and gastric irritation are expected
in clinical use, as no serious side effects have been de-
scribed [7]. Curcumin has a poor bioavailability and
solubility. The major portion of ingested curcumin is ex-
creted through the feces unmetabolized. However, the
small portion that is absorbed is conjugated to glucuronides
and sulfates, in the gut, via UDP-glucuronosyltransferase
(UGT) and sulfotransferase (SULT) enzymes [8, 9]. These
water-soluble metabolites can be delivered to tissues. It
seems possible that curcuminoids deposit in the intercel-
lular lipids of the stratum corneum in a similar manner to
the carotenoids, explaining the predilection of yellowing to
thicker skin areas. Topical application of curcumin to the
human skin is considered beneficial in several skin diseases
but is joined by bright orange-yellow discoloration [10].
Clinical studies did not report skin yellowing as a side
effect of oral consumption of high doses of curcumin or of
curcumin with better bioavailability [11]. To the best of our
knowledge, although known among naturopathic practi-
tioners, this is the first report of yellow skin discoloration
after oral intake of turmeric in the medical literature. Since
the use of turmeric in non-conventional medicine is
growing, it is important for dermatologists and other
practitioners to become familiar with its yellow discol-
oration effects.
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